Eli Lilly (LLY) to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

16 Jun 2025 - 11:45- Equities- Source: PR Newswire

Eli Lilly & CoLLY.USUS EquitiesLLYEli Lilly and CoPharmaceuticals (Group)Pharmaceuticals, Biotechnology & Life SciencesPharmaceuticalsEquitiesS&P 500 IndexEU SessionEU Session

Subscribe Now to Newsquawk

Click here for a 1 week free trial

Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include: